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ABSTRACT 
Astrocytes actively participate in neuro-inﬂammatory processes associated to Alzheimer’s 
disease (AD), and other brain pathologies. We recently showed that an astrocyte-speciﬁc 
intracellular signaling pathway involving an interaction of the phosphatase calcineurin with 
the transcription factor FOXO3 is a major driver in AD-associated pathological 
inﬂammation, suggesting a potential new druggable target for this devastating disease. We 
have now developed decoy molecules to interfere with calcineurin/FOXO3 interactions, 
and tested them in astrocytes and neuronal co-cultures exposed to amyloid-β (Aβ) toxicity. 
We observed that interference of calcineurin/FOXO3 interactions exerts a protective action 
against A-induced neuronal death and favors the production of a set of growth factors that 
we hypothesize form part of a cytoprotective pathway to resolve inﬂammation. 
Furthermore, interference of the A-induced interaction of calcineurin with FOXO3 by 
decoy compounds signiﬁcantly decreased amyloid-β protein precursor (AβPP) synthesis, 
reduced the AβPP amyloidogenic pathway, resulting in lower Alevels, and blocked the 
expression of pro-inﬂammatory cytokines TNFα and IL-6 in astrocytes. Collectively, these 
data indicate that interrupting pro-inﬂammatory calcineurin/FOXO3 interactions in 
astrocytes triggered by Aβ accumulation in brain may constitute an effective new 
therapeutic approach in AD. Future studies with intranasal delivery, or brain barrier 
permeable decoy compounds, are warranted. 
  
INTRODUCTION 
An intense search for new druggable targets to treat Alzheimer’s disease (AD) is underway, 
as no effective treatment is yet in sight. While analyzing the insulin-like growth factor I 
(IGF-I) pathway as a paradigm of endogenous neuroprotective signalling underlying 
responses to brain disease, we recently unveiled an astrocyte-speciﬁc pathway involved in 
resolution of inﬂammation triggered by diverse types of brain injuries, including AD [1, 2]. 
This pathway recruited the phosphatase calcineurin and the transcription factor FOXO, 
both already proposed to be involved in AD pathology [3, 4]. Speciﬁcally, we observed 
that IGF-I disrupts the association of calcineurin with FOXO3 that takes place in response 
to pro-inﬂammatory stimuli such as TNFα or amyloid-β (Aβ). Indeed, calcineurin/FOXO3 
complexes were found in the brain of AD patients, but not in age-matched non-demented 
controls [2]. In this way, IGF-I promotes resolution of the neuro-inﬂammatory cascade by 
halting downstream activation of the canonical pro-inﬂammatory transcription factor NFκB 
[2]. We hypothesized that inhibition of the association of calcineurin with FOXO3 may 
constitute a feasible target to prevent neuro-inﬂammation associated to AD and other 
diseases, and in this way halt or delay neuronal demise. 
Using computer-assisted drug design, we discovered a series of decoy compounds that 
interfere with the association of calcineurin with FOXO3 in response to pro-inﬂammatory 
stimuli. Two of these peptide-mimetics showed good neuroprotective proﬁle in an in vitro 
system mimicking A-induced neuronal injury. 
MATERIALS AND METHODS 
Materials and animals 
C57BL6/J (wild type, wt) and APP/PS1 with C57BL6/J background (a kind gift from P. 
Mouton, NIH) mice were used. Animals were used according to European (86/609/EEC & 
2003/65/EC, European Council Directives) guidelines and studies were approved by the 
Madrid Government Bioethics Committee. 
Bacterial lypopolysaccharide (LPS) was from Sigma (St. Louis, USA), and Aβ40 was from 
Polypeptide (Strasbourg, France). Antibodies against activated caspase 3 (Cell Signaling, 
USA, a marker of apoptotic cells), Aβ (6E10 from BioLegend (1/6000), and 82E1 from 
IBL (1/5000) were used in combination), β3-tubulin (1/5000; Promega, USA, a neuronal 
marker), GFAP (Sigma, an astrocyte marker), β-tubulin (1/2000; Sigma), calcineurin (Cell 
Signaling), FOXO3 (Cell Signaling), IGF-I (Abcam, UK), IGF-II (Abcam), FGF-8 (Santa 
Cruz, USA), sAβPPα (IBL-America, USA), and BSA (Santa Cruz) were all used at a 
1/1000 dilution except when indicated otherwise. Secondary antibodies were goat anti-
rabbit or mouse HRP- (1/20000, BioRad, USA) or Alexa Fluor 488 or 594 donkey anti-
mouse or rabbit (1/1000, Molecular Probes, USA). 
Protein expression and puriﬁcation 
Vectors pGEX-6P-1-human Calcineurin and pGEX-4T3-human FOXO3 were purchased 
from Addgene (plasmids #13251 and #1790). Recombinant calcineurin and FOXO3 GST-
fusion proteins were expressed in E. coli BL21(DE3) (Invitrogen) strain [5]. Cultures were 
grown at 280 rpm and 37◦C until they reached an OD595 of 0.5–0.8, and expression was 
induced by addition of 1 mM IPTG for 4 h. Bacteria cells were then lysed with 1 mg/ml 
lysozyme, 1% Triton X-100, as reported previously [6] with modiﬁcations, such as the 
addition of 0.5%Tween-20 and sonication pulses. Recombinant proteins were puriﬁed by 
GST-afﬁnity chromatography using GSTrap HP columns (GE Healthcare, USA) on an 
FPLC apparatus ( ÄKTA Puriﬁer, GE Healthcare), with a buffer system consisting of 10 
mM sodium phosphate, 0.14 M NaCl, pH 7.4 and 50 mM Tris-HCl, 10 mM reduced 
glutathione, pH 8.0 for binding and elution, respectively. A size-exclusion chromatography 
on a HiLoad 16/60 200 PG column (GE Healthcare) using PBS pH 7.4 was performed after 
GST-afﬁnity chromatography puriﬁcation. For both proteins, ∼90% purity at the end of the 
puriﬁcation procedures was reached, as estimated by SDS-PAGE electrophoresis. Finally, 
the puriﬁed fractions were concentrated (up to 50 M) and the buffer exchanged to 1 mM 
pH 7.4 by ultraﬁltration using Amicon Ultra-15 10K ﬁlters (Millipore, Germany), prior to 
performing the pull-down assays. Protein concentration was determined by absorbance at 
280 nm using its calculated molar extinction coefﬁcient. 
Pull-down assays 
GST fusioned to wild type calcineurin or wild type FOXO3 proteins were employed as 
baits in pull-down experiments. Glutathione Sepharose 4B prepack columns (GE 
Healthcare) were washed with binding buffer (PBS pH 7.4), and equilibrated with PBS, 1% 
Triton X-100 for 30 min at room temperature. One ml of lysates of CHO K1 cells 
transfected with calcineurin (a kind gift of JM Redondo, CNIC) or FOXO3 (Addgene) 
mutant constructs was added to the GST fusion protein columns for 30 min. Columns were 
then washed ﬁve times with binding buffer, and the bound protein was eluted in 50 mM 
Tris-HCl, 10 mM reduced glutathione pH 8.0, dissolved in 5% β-mercaptoethanol Laemli 
buffer and analyzed by western blotting. 
Virtual screening 
Our strategy for the discovery of new hits was carried out by virtual screening, using as 
template a pharmacophore deﬁned from the analysis of the crystal structure of the complex 
of calcineurin with the calcineurin-inhibiting domain of the African Swine Fever Virus 
Protein A238L (entry 4F0Z of the pdb)[7]. In this structure, the A238L peptide 
competitively inhibits calcineurin by occupying the critical substrate recognition site 
φLxVP, while leaving the catalytic center fully accessible (Fig. 1A). 
Analysis of the crystal structure allowed identifying several chemical groups putatively 
critical for the peptide-calcineurin interaction. Accordingly, we deﬁned a ﬁve point 
pharmacophore that consisted in two hydrogen bond acceptors points (F1 and F2), one 
hydrogen bond donor (F3), and two hydrophobic or aromatic points (F4 and F5). An 
exclusion volume was added to simulate the receptor surface, in order to avoid molecules 
clashing with the receptor. The pharmacophore was used as query for a search on the lead-
like compound database of the MOE program (ca. 650.000 compounds) [8]. The search 
yielded a total of 3285 hits that fulﬁlled the pharmacophore hypothesis. These molecules 
were subsequently submitted to a docking process onto the φLxVP site, using the program 
Glide with the SP scoring function [9]. Molecules in their bioactive conformations were 
subsequently analyzed for pharmacophore fulﬁllment, revealing that only 509 molecules 
fulﬁlled at least four pharmacophoric points. Of this subset, only those with a docking 
score (SP) greater than 5 were subsequently grouped into 20 clusters, following a 
hierarchical clustering analysis. For this purpose, molecules were classiﬁed by means of a 
three-point pharmacophore ﬁngerprint, and their distance measured by the Tanimoto 
coefﬁcient, using the program Canvas of Schrödinger software [10]. From the cluster 
analysis we selected one representative of each cluster for testing. However, only 11 
molecules could be acquired and tested (compounds A CN 001, A CN 002, A CN 003, A 
CN 005, A CN 006, A CN 008, A CN 009, A CN 010, A CN 011, A CN 013, and A CN 
014). Based on the results, another 10 compounds were selected from the clusters where 
active compounds had been found (compounds A CN 005 and A CN 006): A CN 15 to A 
CN 24. Finally, we selected 6 additional compounds structurally related to the most active 
compound found (A CN 006): A CN 027 to A CN 32. 
In vitro cultures 
Pure astroglial cultures (>95% GFAP+, OX-42–, A2B5– cells) were prepared as described 
[1]. Brieﬂy, postnatal (day 3–4) mice were rapidly decapitated to minimize suffering, and 
their brains dissected and immersed in ice-cold DMEM/F-12 (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS). Cortex and hippocampus were removed and cut into 1 
mm pieces. Tissue fragments were dissociated mechanically, and the resulting cell 
suspension was centrifuged (1000 rpm/10 min) and plated in DMEM/F-12 with 10% FBS, 
5 × 105 cells per well. Cultures were allowed to grow for 2 days. Pure neuronal cultures 
were obtained as described [1]. Astrocyte-neuron co-cultures were prepared as follows: 
Astrocytes were plated, and when they were 70% conﬂuent, the medium was removed and 
neurons were plated onto them with freshly added medium (Neurobasal+B27 (Invitrogen), 
4 mM glutamine, and 25 mM KCl). Cultures were allowed to grow for 7 days. In 
experiments using wild type (wt) cultures, cells were exposed for 16 h to 10 nM LPS or 2 
µM Aβ prior to adding decoy compounds, and cell death was assessed 2 h later. Cytoxicity 
was determined with the MTT assay following the manufacturer’s instructions. 
Immunoﬂuorescence 
Immunocytochemistry was performed as described [11]. Cells were plated on 20 mm 
coverslips and ﬁxed. Coverslips were blocked with 5% normal horse serum, and incubated 
overnight at 4◦C with the respective primary antibody in phosphate buffer (PB) containing 
0.1% bovine albumin, 3% horse serum, and 0.2% Triton X-100. After several washes in 
PB, sections were incubated with an Alexa Fluor 488 or 594 donkey anti-mouse or rabbit 
(1/1000, Molecular Probes). Omission of primary antibody was used as control. Neuronal 
death was determined by a single investigator in blinded cultures, as described [12]. 
Confocal analysis was performed in a Leica microscope (Leica Microsystems, Germany). 
Immunoassays 
Cultured cells were homogenized in ice-cold buffer consisting of 10 mM Tris HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% NP40, 1 mM sodium 
orthovanadate, and a protease inhibitor cocktail (Sigma) plus 2 mM PMSF. Western blot 
and immunoprecipitation were per-formed as described [1]. Western blot membranes were 
reblotted with either the same antibody used for immunoprecipitation, or with anti-β-
tubulin or anti-bovine serum albumin as internal standards, and to normalize for protein 
load. Levels of the protein under study were expressed relative to protein load in each lane. 
Densitometric analysis was performed using Quantity One software (BioRad). 
Quantitative PCR 
The ﬁrst strand cDNA was synthesized from RNA using the RT2 First Strand Kit 
(SABiosciences). The ΔΔCt method was used to analyze the expression level of each gene 
using the Data Analysis Template provided by SABiosciences. After PCR, the dissociation 
curve for each gene was examined to exclude those with nonspeciﬁc ampliﬁcation, or with 
undetectable expression. Quantitative real-time PCR was performed using an ABI Prism 
7500 detection System (Applied Biosystems). 
Statistics 
Statistical analyses were performed with a t-test when comparing two groups, and a two-
way ANOVA for comparing multiple groups. Statistical signiﬁcance was established when 
p < 0.05. Results shown are mean ± SEM. 
RESULTS 
Using pull-down assays with several FOXO3 and calcineurin mutants, we mapped regions 
involved in FOXO3-calcineurin interaction at residues 468–673 of FOXO3 and 347–521 of 
calcineurin (Supplementary Figure 1A). We then used computer-assisted design to discover 
a series of decoy compounds directed to interfere with the binding region of calcineurin 
with FOXO3. Different series of such compounds (ACN01–ACN032) were tested in 
cultured astrocytes under inﬂammatory challenge, using LPS (10 nM) to promote 
association of calcineurin with FOXO3 [1]. Using this assay, we identiﬁed compounds 
ACN018 and ACN030, -two ((1,3,4-oxadiazol-2-yl) methyl) carbamate analogs with 
diverse substituents, displaying the greatest inhibition on calcineurin/ FOXO3 interactions 
(Fig. 1B), without affecting cell viability (Supplementary Figure 1B). 
Next, we tested the capacity of these compounds to interfere with A-induced neuronal 
death. We hypothesized that if they are able to counteract pro-inﬂammatory signaling in 
astrocytes and re-direct them toward resolution of inﬂammation, treated astrocytes would 
become more neuroprotective. Importantly, under culture conditions only neurons die upon 
Aβ challenge, as indicated by neuronal-speciﬁc immunostaining of activated caspase 3, a 
marker of apoptosis (Fig. 1C). On the other hand, neurons exposed to Aβ do not show 
calcineurin/FOXO complexing (Fig. 1D). The latter indicates that calcineurin/FOXO3 
complexes in co-cultures exposed to pro-inﬂammatory challenge originate only in 
astrocytes, conﬁrming previous observations of an essential role of astrocytes in mediating 
Aβ neurotoxicity in culture [13]. When either compound 018 or 030 were added to co-
cultures exposed to Aβ (2 µM), levels of activated caspase 3 drastically decreased, as 
compared to control co-cultures (Fig. 1E). Furthermore, protection against Aβ-induced 
neuronal death provided by these compounds was linked to a decrease in the reported Aβ-
induced increase in AβPP [14], and in its resultant increased amyloidogenic processing. 
Thus, as shown in Fig. 2, AβPP mRNA and Aβ levels were reduced after addition of 018 or 
030. To conﬁrm an effect of 018 and 030 on AβPP/Aβ levels, we treated astrocyte-
neuronal co-cultures obtained from APP/PS1 mice, that produce abnormally high levels of 
AβPP [15], with these compounds. We conﬁrmed that levels of AβPP mRNA and Aβ were 
also signiﬁcantly reduced (Fig. 2). 
When calcineurin/FOXO3 interactions are interfered in vivo after inﬂammatory injury, 
brain levels of different neurotrophic factors greatly increased [2]. As indicated above, we 
consider that this neurotrophic response forms part of the resolution of inﬂammation. Thus, 
we tested in cultured astrocytes whether a similar neurotrophic effect is observed when 
calcineurin/FOXO3 interactions are interfered with decoy compounds. We measured IGF-
I, IGF-II, and FGF-8 because they were previously found to show highest increases after 
calcineurin/FOXO3 uncoupling [2]. Since interfering with calcineurin/FOXO3 interactions 
modulates AβPP processing (Fig. 2), we also determined the effect of compounds 018 and 
030 on sAβPPα levels, a neurotrophic derivative of AβPP [16] that modulates AβPP 
processing [17]. As shown in Fig. 3, we found that cultured astrocytes exposed to Aβ 
showed increased levels of these neurotrophic proteins when either decoy compound was 
added. Moreover, in astrocytes from APP/PS1 mice, these neurotrophic factors also 
increased in response to compounds 018 and 030 (Fig. 3C). Accordingly, expression of 
pro-inﬂammatory cytokines TNFα and IL-6 in astrocytes, that was increased in response to 
Aβ challenge, was also attenuated. The inhibitory action of these compounds was seen both 
in wild type astrocytes exposed to A, and in astrocytes from APP/PS1 mice (Fig. 4). 
DISCUSSION 
The present results indicate that interfering calcineurin/FOXO interactions, that take place 
during pro-inﬂammatory activation in astrocytes, using decoy molecules, may represent a 
feasible new approach to treat neuro-inﬂammatory damage associated to brain amyloidosis 
in AD. An advantage of this approach is that association of calcineurin with FOXO3 in 
response to inﬂammatory stimuli does not take place in neurons, which reduces possible 
off-target effects. Our observations lend support to future studies using either intranasal 
delivery of this type of decoy compounds or, alternatively, develop similar compounds able 
to cross the blood-brain barrier for systemic administration. Because previous in vivo 
models showed that inhibition of calcineurin/FOXO interactions is sufﬁcient to 
signiﬁcantly delay brain amyloidosis, and prevent, or even revert, cognitive decline in AD 
mice [2], we anticipate similar therapeutic actions for these type of decoy compounds when 
used in vivo. Furthermore, the present results indicate that the interaction between 
calcineurin and FOXO3 in astrocytes is also instrumental in neuronal death elicited by Aβ, 
which opens the possibility that the use of similar compounds in AD patients may also halt 
neuronal death. However, this possibility will require additional studies. 
Until now, anti-inﬂammatory approaches to treat AD have failed [18]. This strategy was 
initiated as a result of epidemiological observations supporting a role of inﬂammation in 
AD, as patients receiving non-steroidal anti-inﬂammatory compounds showed protection 
against the disease [19]. Diverse short-comings may account for a lack of effect of anti-
inﬂammatory therapies in AD patients. Thus, depending on the anti-inﬂammatory used, 
very different outcomes on inﬂammatory pathways may be expected. Further, regulation of 
inﬂammatory cytokines is context- and stage-dependent, so established tauopathy or 
functional disturbances related to neuronal loss may not be counterbalanced [20]. However, 
the strategy that we propose to use is based on cell-speciﬁc (astrocytes) pro/anti-
inﬂammatory pathways, which until now has not been considered. Activation of 
calcineurin is important in the response to pro-inﬂammatory stimuli such as 
TNF                                                     [21], and we previously documented that calcineurin 
activation participates in both progression and resolution of inﬂammation, depending on 
upstream activators such as TNFα or IGF-I, respectively [1]. By inhibiting the interaction 
of calcineurin with FOXO3, this pathway is re-directed towards resolution of inﬂammation. 
Lowering inﬂammation will reduce AβPP synthesis [22, 23], as we now observed. In turn, 
an increased output of neuroprotective mediators will probably reduce amyloidogenic 
AβPP processing [2, 22]. Indeed, increased levels of sAβPPα together with decreased 
production of Aβ peptides were detected. sAβPPα also inhibits BACE-1 activity, which in 
turns will reduce Aβ levels [24], as we observed now in cultured astrocytes. 
In summary, pharmacological manipulation of an astrocyte-speciﬁc pro-inﬂammatory 
pathway that interferes with the association of the phosphatase calcineurin with the 
transcription factor FOXO3, protects neurons against A-induced cell death. Cell-speciﬁc 
anti-inﬂammatory drugs may open a new avenue to treat neuro-inﬂammation associated to 
AD and other neurodegenerative diseases. 
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CAPTIONS TO FIGURES 
Figure 1. Decoy compounds that interfere with calcineurin and FOXO3 interactions. A) 3D 
model of the complex of calcineurin with the calcineurin-inhibiting domain of the African 
swine fever virus protein A238L. The position of the substrate recognition site φLxVP is 
shown. Calcineurin A (CNA) and B (CNB) moieties are indicated. B) Example of the 
screening system used to identify compounds that interfere with the association of 
calcineurin with FOXO3 upon stimulation of astrocytes with LPS (10 nM). ACN 
compounds 018 and 030 displayed the highest activity. Lanes: 1: vehicle (DMSO), 2: 
Dexamethasone+LPS, 3: vehicle+LPS, 4: ACN015+LPS, 5: ACN016+LPS, 6: 
ACN017+LPS, 7: ACN018+LPS, 8: Vehicle, 9: Dexamethasone+LPS, 10: Vehicle+LPS, 
11: ACN026+LPS, 12: ACN029+LPS, 13: ACN030+LPS. All compounds were tested at 
10 µM. C) Neurons, but not astrocytes, die after challenged with Aβ (2 µM). Thus, 
activated caspase 3 staining (red) was found only in neuronal cultures (β3-tubulin+ cells in 
green) but not in astrocytes (GFAP+, in green). D) Neurons (Neu) in culture do not show 
association of calcineurin with FOXO3 after LPS or Aβ challenge. Cultured astrocytes (As) 
that show association of FOXO3 with calcineurin were used as positive controls. E) 
Compounds ACN 018 and 030 showed the greatest inhibitory activity on Aβ-induced 
neuronal death. Neurons were cultured with astrocytes and challenged with Aβ (2 µM). 
Twenty-four hours later activated caspase levels were measured by western blot in culture 
lysates. Bars in the right show quantiﬁcation of blots. Lanes: 1: Control, 2,3: Aβ, 4,5: 
ACN018+Aβ, 6,7: ACN030+A, 8: ACN030. (∗∗p < 0.01 versus Aβ and ∗∗∗p < 0.001 
versus control, n = 3). All compounds were tested at 10 µM. When given alone, neither 
compound affected neuronal viability (not shown). 
Figure 2. Interfering calcineurin/FOXO3 interactions reduces levels of AβPP mRNA and 
its amyloidogenic processing. A) ACN018 and 030 reduce levels of AβPP mRNA in wild 
type astrocyte-neuronal co-cultures exposed to A, and in astrocyte-neuronal co-cultures 
from APP/PS1 mice, B) Similarly, ACN018 and 030 reduce levels of Aβ in wild type 
astrocyte-neuronal co-cultures exposed to Aβ and in astrocyte-neuronal co-cultures from 
APP/PS1 mice. Representative blots using in combination anti-Aβ antibodies 6E10 and 
82E1. Monomer and dimer forms of Aβ are shown. Quantitation histograms are shown 
below. (*p < 0.05, **p < 0.01 and ∗∗∗p < 0.001 versus control, n = 5). 
Figure 3. ACN018 and 030 stimulate the release of neurotrophic factors in astrocytes 
exposed to inﬂammatory challenge. A, B) In the presence of LPS (A) or Aβ (B), ACN018 
and 030 stimulate the secretion of IGF-I, IGF-II, FGF-8, and sAβPPα. C) Astrocytes 
derived from APP/PS1 mice show enhanced secretion of IGF-I, IGF-II, FGF-8, and 
sAβPPα when cultured in the presence of ACN018 or 030. Normalization of protein load 
was performed with bovine serum albumin (BSA) from culture supernatants. 
Figure 4. Compounds 018 and 030 decrease mRNA levels of pro-inﬂammatory cytokines 
TNFα (left chart) and IL-6 (right) that are increased after exposure of wild type astrocytes 
to Aβ or in APP/PS1 astrocytes (∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 versus control, n = 
5). 
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